Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of SMMT is 33 and suggests 108% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell